| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total other income (expense), net | 1,845 | 1,559 | 1,922 | |
| Net loss before income taxes | -19,014 | -20,256 | - | |
| Income tax expense (benefit) | - | -681 | - | |
| Net loss | -19,014 | -19,575 | -22,845 | |
| Other comprehensive income - unrealized gain (loss) on short-term investments | 23 | -30 | 347 | |
| Comprehensive loss | -18,991 | -19,605 | -22,498 | |
| Net loss per share, basic | -0.21 | -0.26 | -0.32 | |
| Net loss per share, diluted | -0.21 | -0.26 | -0.32 | |
| Weighted average number of share outstanding basic and diluted | 89,418,028 | 75,547,746 | 71,084,787 | |
| Weighted average number of shares outstanding, diluted | 89,418,028 | 75,547,746 | 71,084,787 | |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)